Analysts See $-0.58 EPS for ACADIA Pharmaceuticals Inc. (ACAD)

October 13, 2018 - By Peter Erickson

Investors sentiment increased to 1.22 in 2018 Q2. Its up 0.33, from 0.89 in 2018Q1. It increased, as 31 investors sold ACADIA Pharmaceuticals Inc. shares while 43 reduced holdings. 35 funds opened positions while 55 raised stakes. 114.30 million shares or 4.25% less from 119.37 million shares in 2018Q1 were reported.
Envestnet Asset Management owns 619 shares. Ing Groep Nv has 0.13% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Riggs Asset Managment Incorporated has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 650 shares. Ameriprise Fincl, a Minnesota-based fund reported 942,228 shares. Prudential Fincl invested in 11,640 shares or 0% of the stock. Pdts Prns Limited Liability stated it has 681,500 shares. Barclays Pcl holds 0% or 98,538 shares in its portfolio. Kistler stated it has 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Northern Trust accumulated 1.27M shares. Advisors Asset Mgmt, Colorado-based fund reported 108 shares. Millennium Lc invested in 680,624 shares or 0.01% of the stock. Metropolitan Life Ins Ny holds 0% or 32,357 shares. Mark Sheptoff Financial Planning Ltd Liability has invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). 60,000 were reported by Hikari Limited. Moreover, California Employees Retirement Sys has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Since September 20, 2018, it had 1 buying transaction, and 0 insider sales for $22.65 million activity.

Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report $-0.58 EPS on November, 6.They anticipate $0.05 EPS change or 9.43 % from last quarter’s $-0.53 EPS. After having $-0.51 EPS previously, ACADIA Pharmaceuticals Inc.’s analysts see 13.73 % EPS growth. The stock increased 3.48% or $0.73 during the last trading session, reaching $21.72. About 1.65M shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 62.95% since October 13, 2017 and is downtrending. It has underperformed by 78.57% the S&P500.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Among 5 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. ACADIA Pharmaceuticals had 6 analyst reports since August 6, 2018 according to SRatingsIntel. JMP Securities maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating on Thursday, August 9. JMP Securities has “Market Outperform” rating and $27 target. On Friday, September 21 the stock rating was upgraded by PiperJaffray to “Overweight”. The stock has “Buy” rating by Bank of America on Wednesday, October 10. The rating was downgraded by PiperJaffray on Monday, August 6 to “Neutral”.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $2.72 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

More important recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: Fool.com which released: “Here’s Why Acadia Pharmaceuticals Inc. Spiked Over 26% Today” on September 20, 2018, also Seekingalpha.com published article titled: “Acadia Survives CNN ‘Bear Attack'”, Seekingalpha.com published: “Premarket Gainers as of 9:05 am” on September 21, 2018. More interesting news about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was released by: Seekingalpha.com and their article: “Acadia’s Big Scores” with publication date: September 27, 2018.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>